Type 2 innate lymphoid cells: at the cross-roads in allergic asthma by unknown
REVIEWARTICLE
Type 2 innate lymphoid cells: at the cross-roads in allergic asthma
Leonie van Rijt1 & Helen von Richthofen1 & Ronald van Ree1,2
Received: 30 October 2015 /Accepted: 9 February 2016 /Published online: 10 March 2016
# The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract Allergic asthma is a chronic inflammatory disease
of the lower airways that affects millions of people worldwide.
Allergic asthma is a T helper 2 cell (Th2)-mediated disease, in
which Th2 cytokines interleukin (IL)-4, IL-5, and IL-13 are
closely associated with the symptoms. IL-4 is needed by B
cells to switch toward an IgE response, IL-5 recruits and acti-
vates eosinophils while IL-13 increases mucus production.
The identification of type 2 innate lymphoid cells (ILC2),
which are able to rapidly produce large amounts of IL-5 and
IL-13 in response to epithelial derived cytokines, implicated a
new key player besides Th2 cells. ILCs constitute a family of
innate lymphocytes distinct from T and B cells. ILC2s are
located in various epithelial compartments in mice and hu-
man, including the lung. The recent finding of increased num-
bers of ILC2s in the airways of severe asthma patients prompts
further research to clarify their immunological function.
Murine studies have shown that ILC2s are an early innate
source of IL-5 and IL-13 after allergen exposure, which in-
duce airway eosinophilic infiltration, mucus hyperproduction,
and airway hyperresponsiveness but not allergen-specific IgE
production. ILC2s contribute to the initiation as well as to the
maintenance of the adaptive type 2 immune response. Here,
we review the recent progress on our understanding of the role
of ILC2s in the immunopathology of allergic asthma, in par-
ticular by studies using murine models which have elucidated
fundamental mechanisms by which ILC2s act.
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Introduction
Asthma is a chronic inflammatory airway disease that is char-
acterized by airway hyperresponsiveness (AHR), eosinophilic
inflammation, and mucus hyperproduction. Clinical symp-
toms include recurrent wheezing, coughing, and shortness of
breath [1]. More than 300 million people worldwide are af-
fected by asthma, making it one of the most common chronic
diseases [2].
Th2 cells are the central players in allergic asthma, as they
are major producers of the type 2 cytokines interleukin-4 (IL-
4), IL-5, and IL-13, which are all tightly linked to the patho-
genesis of asthma [3]. IL-4 induces IgE production by B cells,
which can bind to high affinity Fcε receptors (FcεRI) on mast
cells and basophils [4]. IL-5 activates eosinophils and attracts
them to the lung, where they secrete numerous inflammatory
cytokines and chemokines [5]. IL-13 directly affects the air-
way epithelium and smooth muscle cells in the lungs and
thereby contributes to AHR, mucus hyperproduction, and, in
persistent inflammation, to airway remodeling [6]. Current
effective treatment of asthma is aimed at the suppression of
symptoms by bronchodilators in combination with anti-
inflammatory drugs, and only recently, this has been com-
bined with therapies that target specific underlying immuno-
logical processes.
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The key role for Th2 cells in driving allergies was chal-
lenged by the observation that mice with an absent adaptive
immune system are still able to mount a strong type 2 response
[7, 8]. This finding led to the identification of a previously
unrecognized innate cell population, which was named type
2 innate lymphoid cell (ILC2) [9]. ILCs are classified into
three different types, based on a similar cytokine profile cor-
responding to the helper T subsets Th1, Th2, and Th17, re-
spectively. ILC2s lack the specific antigen receptor of Th2
cells, yet provide an important source of type 2 cytokines
and are therefore potential new players in type 2 immunity
and allergic asthma [10].
In this review, wewill describe how ILC2s interact with the
innate and adaptive immune system and thereby contribute to
the immunopathology of allergic asthma. This cell population
might be an attractive therapeutic target in the treatment of
allergic asthma.
IL-5 and IL-13 production by pulmonary ILC2s
Initial studies in mice used IL-25 or IL-33 inhalation to show
that pulmonary ILC2s are capable of producing IL-5 and IL-
13 after in vivo activation but secrete very little IL-4 [10–12].
These results were soon extended, as it was shown that pul-
monary ILC2s have the capacity to produce large amounts of
IL-5 and IL-13 after intranasal challenge with various aller-
genic substances, including ovalbumin (OVA) [10, 13], the
protease papain [14, 15], house dust mite (HDM) [10],
Alternaria alternata products [16, 17], glycolipid antigens
[18], and the nonprotease allergen chitin, a polysaccharide
from fungi, parasites and arthropods, known to induce Th2
cell-independent innate type 2 responses [19, 20]. In addition,
IL-5 and IL-13 production by pulmonary ILC2s could be in-
duced by influenza infection [21, 22] or pulmonary helminth
infection [23]. Together, this indicates that ILC2s play an im-
portant role in immune responses to various intruding patho-
gens but are also involved in the aberrant immune response to
allergens.
To determine the relevance of IL-5 and IL-13 production
by ILC2s, their capacity to produce these cytokines should be
compared to that of Th2 cells. After IL-25 inhalation, ILC2s
constituted 50 % of IL-5+ cells and IL-13+ cells in the lung,
and after IL-33 inhalation, this was even 80 % [10]. However,
IL-25 or IL-33 treatment does not induce full T cell activation
and might therefore overestimate the contribution of ILC2s to
type 2 cytokine production [24]. Nevertheless, also in HDM-
and OVA-induced asthma models, ILC2s produced a substan-
tial part of the type 2 cytokines. After HDM challenge, the IL-
5+ ILC2 population in the lung was approximately half the
size of the IL-5+ Th2 cell population, and in the bronchoalve-
olar lavage fluid (BAL), these populations even had a similar
size. Similar results were found when comparing IL-13+
ILC2s and IL-13+ Th2 cells after HDM challenge [10].
These results suggest that ILC2s contribute significantly to
IL-5 and IL-13 production in murine models of allergic asth-
ma. In support, papain treatment induced IL-5 and IL-13 se-
cretion in lung explants from Rag1−/− mice (which have
ILC2s but are deficient for T, B, and NKT cells), but not in
lung explants from ILC-deficient Rag2−/−Il2rg−/−mice (which
have no ILCs or other lymphocytes). Intracellular staining
confirmed that the majority of IL-5+ and IL-13+ cells were
indeed ILC2s [25]. The close proximity of lung ILC2s to
medium-sized blood vessels explains how IL-5 could be re-
leased in the blood stream as a signal for the bone marrow to
increase its eosinophil production [26].
Understanding activation of ILC2s
ILC2s can be activated by various cytokines, and particularly
epithelial cell-derived cytokines IL-25, IL-33, and TSLP have
been shown to initiate ILC2 responses in both mice and
humans [27]. These innate type 2 response-promoting cyto-
kines can be released after inhalation of allergens. In addition,
recently, other soluble factors have been reported to activate
ILC2s, including prostaglandins [28–30] and leukotrienes
[16]. Activation of ILC2s is defined by their expansion and
type 2 cytokine production. Expansion of ILC2s can be
achieved by recruitment of ILC2s to the site of challenge
[22] as well as by in situ proliferation of resident cells [16, 17].
Epithelial cell-derived cytokines IL-25, IL-33, and TSLP
Mouse ILC2s can be activated by IL-25 [12, 31], IL-33 [18,
32–35], and TSLP [19, 25, 36], in vitro and in vivo. Recently,
the main source of IL-33 and TSLP in response to chitin
exposure was identified to be alveolar type II cells of the distal
airways [20]. However, the relative importance of these cyto-
kines in activating ILC2s is less clear and seems to vary in
different locations and experimental settings. For example, a
study by Neill et al. suggested that IL-25 is more potent than
IL-33 in activating ILC2s in vivo, as ILC2 expansion in mes-
enteric lymph nodes was less impaired in Ilrl1−/− (IL-33R
subunit) mice than in Il17br−/− (IL-25R subunit) mice in re-
sponse to helminth infection [31]. Conversely, challenge of
the same mouse strains with ragweed pollen or ovalbumin
via the airways indicated that IL-33 is faster and more potent
than IL-25 in promoting pulmonary ILC2 activation and AHR
[37]. Chitin exposure induced contemporaneous expression of
IL-33 and TSLP. The short coexpression of TSLP was shown
to synergize with IL-33 to induce IL-5 and IL-13 production
[20]. In contrast, Kim et al. found that skin ILC2s were inde-
pendent of both IL-25 and IL-33 treatment, but instead relied
on TSLP for their activation [36].
Studies in humans also suggest synergizing and varying
roles for IL-25, IL-33, and TSLP in activating ILC2s.
Mjösberg et al. found that ILC2s from human fetal gut or
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peripheral blood were activated in vitro in response to treat-
ment with either IL-25 or IL-33, as long as it was combined
with IL-2 treatment [38]. The same authors showed that TSLP
alone could activate ILC2s from human peripheral blood in
vitro by enhancing GATA-3 expression [39]. Conversely,
Salimi et al. found that ILC2s from human skin were only
activated directly by IL-33, whereas simultaneous treatment
with IL-25 and TSLP could enhance IL-33-induced cytokine
production in vitro [40]. This result corresponds to a study that
investigated activation of mouse ILC2s in vitro, where IL-25
did not activate lung ILC2 directly, but only amplified the
response of ILC2 that were activated by IL-33 plus IL-2, IL-
7, or TSLP [25].
Interestingly, intranasal exposure to IL-25 evoked a second
IL-13-producing ILC2 population (IL-17RB+/ST2−/CD127lo/
KLRG1hi) which were called inflammatory ILC2s. This pop-
ulation was also induced after infection with Nippostrongylus
brasiliensis. However, this increase was transiently and
iILC2s seemed to act as a precursor for natural ILC2s, as they
acquired expression of ST2 and responsiveness to IL-33 dur-
ing ongoing inflammation. TheN. brasiliensis induced iILC2s
were also dependent on IL-25, as they were absent in IL-25
receptor (Il17rb−/−) knockout mice [41].
Together, these results indicate that IL-25, IL-33, and TSLP
are all able to activate ILC2s, but that their relative contribu-
tion to this activation depends on the tissue, experimental
setting, and state of disease. The redundancy of these cyto-
kines in activating ILC2s has therapeutical implications, as
targeting just one of these cytokines to inhibit ILC2s may
not give satisfactory results. Indeed, studies in mice show that
ILC2 activation in response to helminth infection [31] or A.
alternata exposure [34] is only completely abolished in com-
bined absence of IL-25 and IL-33 signaling. Moreover, ILC2
activation in response to chitin inhalation was only abolished
in combined absence of IL-25, IL-33, and TSLP signaling
[19].
Other cytokines: IL-2, IL-7, IL-9, and TL1A
In addition to epithelial cell-derived cytokines, other cytokines
have been shown to enhance ILC2 activation. Several studies
report that costimulation with IL-2 and/or IL-7 is required to
activate ILC2 with epithelial cell-derived cytokines in vitro.
For example, mouse ILC2 could only be activated by IL-33 in
presence of IL-2 or IL-7 [21, 25]. Likewise, human ILC2s
required presence of IL-2 to be activated by IL-25 or IL-33
[38]. In addition, studies report independent effects of IL-2
and IL-7. ILC2s that were isolated from fat-associated lym-
phoid clusters (FALCs) proliferated in response to IL-2 treat-
ment in vitro [32]. Culturing lung ILC2s on OP9 stromal cells
with IL-2 or IL-7 supported the survival but not expansion of
ILC2s [25]. However, although the requirement for IL-7 sig-
naling in ILC2 development is well established, its role in
ILC2 activation in vivo remains to be confirmed. It was re-
cently demonstrated that IL-2 might activate ILC2s in vivo, as
injection of Rag1−/−mice (which lack T, B, and NKTcells but
do have ILC2s) with IL-2-anti-IL-2 antibody complexes
(which facilitate slow release of IL-2) increased ILC2 num-
bers in the lung, mesenteric LN, spleen, and skin [13, 42, 43].
IL-2-induced ILC2 expansion also correlated with efficient
worm expulsion [13]. The responsiveness to IL-2 has interest-
ing implications, as T cells are the main source of IL-2 in vivo
and might therefore regulate ILC2 activation and survival
[42]. Indeed, ILC2s were able to expand in N. brasiliensis-
infected Rag2−/− mice (which lack T, B and NKT cells but do
have ILC2s), but their numbers could not be maintained [31].
A number of non-T cell sources for IL-2 have been reported
including dendritic cells, eosinophils and ILC3 (IL-17-pro-
ducing ILCs) [43].
Another cytokine that was reported to enhance ILC2 func-
tion is IL-9 [14, 20, 23]. Blocking IL-9 signaling with neutral-
izing antibodies [14] or by using Il9r−/− mice [23] reduced
ILC2 activation in response to papain inhalation [14] or N.
brasiliensis infection [23]. In addition, IL-9 induced expres-
sion of the antiapoptotic protein BCL3 on ILC2s in N.
brasiliensis-infected lungs, and thereby promoted their surviv-
al [23]. With the use of IL-9 reporter mice, it was shown that
ILC2s themselves provided the major source of IL-9, indicat-
ing that IL-9 acts on ILC2s in an autocrine fashion [14, 23].
Furthermore, IL-9 expression in response to papain treatment
was strongly decreased in Rag1−/− mice compared to WT
mice, and this effect was rescued by application of IL-2, sug-
gesting that IL-9 production by ILC2s is dependent on IL-2
provided by the adaptive immune system [14]. IL-9 was also
induced in response to chitin, resulting in an increased IL-5
and IL-13 production. The IL-9 induction was dependent on
the induction of the transcription factor interferon regulatory
factor 4 [20].
Recently, two studies showed that the TNF-like li-
gand 1A (TL1A) can activate ILC2s [44, 45]. TL1A
was discovered as a costimulatory cytokine that pro-
motes T cell activation by binding to Death receptor 3
(DR3) [46]. Both mouse and human ILC2s constitutive-
ly express DR3 [44, 45]. Yu et al. showed that TL1A
alone could activate mouse ILC2s in vitro as well as in
in vivo, whereas Meylan et al. found that TL1A alone
could only activate ILC2s in vitro. However, both stud-
ies showed that TL1A signaling enhanced IL-33- and
IL-25-induced ILC2 activation in mice, in vivo [44,
45]. The same enhancing effect on IL-33 or IL-25 treat-
ment was found for ILC2s from human peripheral blood
[44]. Together, this suggests that TL1A can act as an
ILC2 costimulator. Interestingly, TL1A is produced by
DCs and macrophages in response to TLR activation or
Fc receptor crosslinking [46], indicating that ILC2 acti-
vation is also regulated by innate immune cells.
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Leukotrienes and prostaglandins
Recently, it was shown that ILC2s can be activated by certain
leukotrienes and prostaglandins. These lipid mediators are as-
sociated with allergic type 2 responses and are produced by
various activated innate immune cells, including mast cells,
eosinophils, macrophages, and dendritic cells [47].
Doherty et al. showed that lung and bone marrow ILC2s
from naive and Alternaria-challenged mice expressed the
cysteinyl leukotriene receptor 1 (CysLT1R). Cysteinyl leuko-
trienes have been associated with allergic asthma in mice [48]
and humans [49]. Treatment with leukotriene D4 (LTD4), a
CysLT1R ligand, activated ILC2s in vitro and in vivo, and
this response could be blocked by treatment with the
CysLT1R antagonist montelukast, which is used in treatment
of allergic asthma [16].
In humans, expression of CRTH2 is commonly used to
identify ILC2s [38]. Prostaglandin D2 (PGD2), a CRTH2 li-
gand, is highly expressed in human mucosal sites and is
known for its chemotactic effects on Th2 cells [50]. It was
therefore hypothesized that PGD2 may also recruit ILC2s to
mucosal tissue [29]. Indeed, PGD2 treatment induced chemo-
taxis and cytokine production by human ILC2s from periph-
eral blood [29, 30] and skin [28], in vitro. This response could
be prevented by treatment with CRTH2 antagonists [28–30].
Mast cells provide a major source of PGD2 during allergic
responses, and ILC2s could be activated by supernatant from
activated human mast cells, but not in the presence of a
CRTH2 antagonist [28].
Barnig et al. identified lipoxin A4 (LXA4) as a negative
regulator of ILC2s [30]. Human ILC2s from peripheral blood
expressed the LXA4 receptor ALX/FPR2, and treatment with
LXA4 decreased cytokine production by activated ILC2s in
vitro [30]. The natural generation of LXA4 is decreased in
severe asthma and implicates unrestrained activation of
ILC2s. This interaction might contribute to the function of
LXA4 as a natural pro-resolving mediator in allergic asthma
[51].
ILC2s in allergic asthma in mice
ILC2s produce several type 2 cytokines and can thereby affect
various cells that are involved in the pathogenesis of allergic
asthma (Fig. 1). ILC2-deficient murine models of allergic
asthma have provided an important tool in elucidating these
interactions, in which comparison of Rag2−/− mice (deficient
in T, B, and NKTcells) with Rag2−/−Il2rg−/−mice (deficient in
T, B, NKT, and ILCs) allowed for the investigation of ILC2
effector functions independent of the adaptive immune sys-
tem, whereas RORα-deficient staggerer (Rorasg/sg) mice pro-
vide a model to investigate ILC2 function in the context of the
adaptive immune system. RORα is an important transcription
factor in ILC2s. RORαsg/sg mice suffer from severe neurolog-
ical defects from birth; therefore, mainly bone marrow
transplantedmice (BMT) are used to prevent neural abnormal-
ities. Transplantation of RORαsg/sg BM in an irradiated host
provides a normal hematological repopulation, except that
BMT mice lack the IL-25 induced expansion of ILC2s [52].
Interaction of ILC2s with innate immune cells
and structural cells
ILC2s contribute to pulmonary eosinophilia
IL-5 is essential for eosinophil development and activation
[53], and therefore, ILC2-derived IL-5 is likely to affect eo-
sinophils. Indeed, several studies suggest that activated ILC2s
contribute to eosinophilic inflammation. For example,
Doherty et al. showed that intranasal Alternaria or LTD4 ad-
ministration induced pulmonary eosinophilia in Rag2−/− mice
(lack T, B, and NKT cells but do have ILC2s), but not in
Il7ra−/−mice, which lack all ILCs in addition to B and T cells
[16, 17]. Likewise, Halim et al. showed that intranasal papain
treatment increased the number of eosinophils in the lungs of
WTand Rag1−/−mice, but not in ILC-deficient Rag2−/−Il2rg−/
−mice. Furthermore, depletion of ILC2s in Rag1−/−mice with
neutralizing CD25 antibodies decreased papain-induced eo-
sinophilia, whereas adoptive transfer of ILC2s into Rag2−/
−Il2rg−/− enhanced papain-induced eosinophilia [25]. These
studies indicate that activated ILC2s induce pulmonary eosin-
ophilia independent of the adaptive immune system.
In a subsequent study, Halim et al. investigated whether
ILC2s affect eosinophilia in the presence of Th2 cells.
Adoptive transfer of WT bone marrow cells into Rag2−/
−Il2rg−/− mice restored papain-induced and IL-25-induced
pulmonary eosinophilia, whereas adoptive transfer of ILC2-
deficient Rorasg/sg bone marrow cells did not. The presence of
other pulmonary leukocytes, including neutrophils, macro-
phages, DCs, NK cells, NKT cells, T cells, and B cells, was
not differentially affected in papain-treated mice that had re-
ceived WT bone marrow cells versus mice that had received
Rorasg/sg bonemarrow cells [54]. Additionally, in an influenza
A virus (IAV)-induced pulmonary inflammation model, in
vivo depletion of ILC2s and T cells with a neutralizing anti-
Thy1.2 antibody in WT mice reduced eosinophil numbers in
the lung, which could be rescued by the adoptive transfer of
total Thy1.1+ cells (which include ILC2 and T cells) but not
CD3+ Thy1.1+ lung cells (which only include T cells) [22].
Together, these results indicate that ILC2s contribute to
eosinophilia in mouse models of allergic asthma, both in the
absence and presence of the adaptive immune system. It
seems likely that this effect is mediated by ILC2-derived IL-
5, yet no study has directly assessed this. The only indication
that ILC2-derived IL-5 is sufficient to induce eosinophilia
came from a recent study that used IL-5 reporter (Red5) mice
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to investigate pulmonary IL-5 production [19]. Red5 mice
express a tdTomato(RFP)-IRES-Cre replacement allele at the
translation start site of the endogenous Il5 gene, resulting in
production of RFP instead of IL-5 upon commitment to Il5
translation [55]. Il5red/red mice (which are IL-5 deficient) had
strongly diminished numbers of eosinophils in the lungs after
repeated chitin inhalation, whereas ILC2 numbers were not
affected. Strikingly, RFP expression was found exclusively
in ILC2s [19], indicating that ILC2-derived IL-5 is critically
required for chitin-induced eosinophilia. In addition, ILC2-
derived IL-13 may also contribute to allergen-induced pulmo-
nary eosinophilia. Chitin-treated Il13−/−Il4−/− mice had re-
duced eosinophil numbers in the lung, whereas Il4−/− mice
had not. The source of IL-13 after challenge with chitin was
confined to ILC2s as elucidated by IL-13 reporter mice
(Il13smart/smart) [19]. In support, Barlow et al. found that IL-
25-induced eosinophilia in the BAL was decreased in Il13−/−
mice compared toWTmice, which could partly be rescued by
the adoptive transfer of WT ILC2, but not by transfer of Il13−/
− deficient ILC2 [56]. Together, these reports suggest that
ILC2-derived IL-5 and IL-13 contribute nonredundantly to
eosinophilia. This corresponds with earlier findings on
allergen-induced eosinophilia, which show that IL-5 promotes
development and survival of eosinophils, whereas IL-13 me-
diates recruitment of eosinophils through secretion of eotaxins
[57]. In line with this, Van Dyken et al. found that chitin
challenge increased expression of eotaxin-1 in the lungs and
that chitin-induced eosinophilia was decreased in mice lack-
ing the eotaxin-1 receptor CCR3 [19].
ILC2s contribute to AHR and mucus hyperproduction
IL-13 acts directly on airway epithelial cells and smooth mus-















































Fig. 1 ILC2 interactions in allergic asthma. The inbetweeners: ILC2s in
the immunopathology of allergic asthma. ILC2s respond to IL-25, IL-33,
or TSLP, which is produced by airway epithelial cells in response to
allergen encounter or infection with helminthes or viruses. In addition,
ILC2s may be activated by innate cell-derived PGD2, LTD4, TL1A, IL-
25, or IL-33. IL-9 activates ILC2s in an autocrine manner. The production
of IL-5 and IL-13 by ILC2s contributes to typical allergic asthma hall-
marks, including pulmonary eosinophilia, mucus hyperproduction, and
AHR. ILC2-derived IL-13 was shown to induce accumulation of
alternatively activated macrophages and promote migration of DCs from
the lung to lymph node. ILC2s also interact with Tcells, likely viaMHCII
expression and possibly via expression of IL-4 and OX40L. In turn, T
cells can activate ILC2s by secreting IL-2. In addition, ILC2smay interact
with B cells, possibly via expression of ICOS-ligand or IL-4. The pres-
ence of ILC2s might also have beneficial effects in allergic asthma, as
their production of amphiregulin (Areg) was shown to promote tissue
repair of the epithelium in pulmonary inflammation
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hyperproduction in allergic asthma [6]. As ILC2s are capable
of producing IL-13 in response to allergen exposure, it is
proposed that ILC2s also contribute to the pathogenesis of
these asthma symptoms.
This hypothesis was supported by an influenza (H3N1)-
induced pulmonary inflammation study. H3N1 infection in-
duced AHR in Rag2−/−mice, which was abolished after ILC2
depletion with a neutralizing Thy1.2 antibody. In addition,
H3N1 infection failed to induce AHR in Il13−/− mice, which
was restored by adoptive transfer of WT ILC2s [21]. ILC2-
derived IL-13 also affected AHR in cytokine- and allergen-
based mouse models of pulmonary inflammation. Kim et al.
found that Il13−/− mice showed reduced AHR after IL-33- or
glycolipid (α-Galcer) inhalation compared toWTmice, which
could be rescued by adoptive transfer of WT ILC2s [18].
Barlow et al. found similar results for IL-25-induced AHR,
and importantly, they showed that adoptive transfer of WT
ILC2s, but not Il13−/− ILC2s, could rescue IL-25-induced
AHR in Il13−/− mice [56]. This indicates that ILC2-derived
IL-13 is sufficient to induce AHR in response to IL-25 inha-
lation. However, the contribution of ILC2-derived IL-13 to
allergen-induced AHR within the context of other IL-13-
producing cells remains to be determined.
Besides the involvement in AHR, some studies suggest that
ILC2s also contribute to mucus hyperproduction in allergic
asthma models. For example, papain inhalation induced mu-
cus hyperproduction in the lungs ofWTand Rag1−/−mice, but
not in the lungs of Rag2−/−Il2rg−/− mice [25]. Furthermore,
adoptive transfer of WT bone marrow cells, but not Rorasg/sg
bone marrow cells, restored papain-induced mucus hyperpro-
duction in Rag2−/−Il2rg−/− mice [54]. These studies are indic-
ative for an effect of ILC2s on mucus hyperproduction, yet
they do not prove that this effect is mediated via IL-13
secretion.
Interactions with macrophages, γδ T cells, ILC3, mast cells,
and basophils
Although these interactions are less well established, it ap-
pears that ILC2s also interact with other innate immune cells
that are involved in allergic asthma.
It was recently suggested that ILC2s may contribute to
allergen-induced accumulation of alternatively activated mac-
rophages (AAMs, also known asM2 macrophages) [19]. IL-4
and IL-13 stimulate differentiation into AAMs, which typical-
ly express arginase-1 and chitinases [58]. AAMs are generally
considered to be anti-inflammatory but are also implied to
play a role in pathogenic type 2 responses [59]. The study that
investigated chitin-induced eosinophilia found that chitin-
challenged ll13−/−Il4−/− mice had reduced AAM numbers in
the lung, whereas Il4−/− mice had not. IL-13 was exclusively
expressed by ILC2s, which suggested that ILC2-derived IL-
13 contributed to chitin-induced AAM accumulation [19].
The same authors crossed Il5Red5/Red5 or Il13YetCre/YetCre
mice with mice that carry a Gt(Rosa)26DTA allele, to create a
mouse model in which cells get killed by diphtheria toxinα as
soon as they commit to IL-5 or IL-13 production, respectively.
Challenging these mice with chitin led to deletion of ILC2s
and a reduction in AAM accumulation and eosinophilia,
which supports earlier findings [19]. Surprisingly, ILC2 dele-
tion also increased the levels of several inflammatory cyto-
kines including TNFα, IL-1β, and IL-23 and increased the
activation of IL-17A-producing γδ T cells, which caused an
increase in airway neutrophilia. Intriguingly, chitin-treated IL-
5- and IL-13-deficient mice had similar numbers of γδ T cells
and neutrophils as WT controls, suggesting that the suppres-
sive effects of ILC2s on γδ T cells and neutrophils were not
mediated via IL-5 or IL-13 signaling [19].
Two recent reports showed colocalization of ILC2s and
mast cells, suggesting an interaction between these cells.
Barnig et al. found ILC2s in the close proximity of mast cells
in the human lung [30]. Roediger et al. used intravital multi-
photon microscopy to track the movement of ILC2s in the
skin of healthy mice and found that ILC2s specifically
interacted with mast cells. Interestingly, these ILC2s constitu-
tively expressed IL-13, and in vitro experiments showed that
IL-13 suppressed the release of TNFα and IL-6 by mast cells,
suggesting an inhibitory effect of ILC2s on mast cells in this
context [42].Mast cells and ILC2smight also interact via mast
cell-derived PGD2 and LTD4, which is released upon allergen
challenge-induced FcεRI cross-linking and might recruit and
activate ILC2s [16, 28–30]. However, this remains to be con-
firmed in vivo and in the context of allergic asthma. Roy et al.
reported that mast cell chymase has the ability to degrade IL-
33, indicating that mast cells can have a regulatory function in
the balance of IL-33, implicating a feedback mechanism on
the activation of ILC2s [60].
One recent study suggested interactions between ILC2s
and basophils, as clusters of ILC2s and basophils were found
in inflamed human and murine skin. The presence of baso-
phils preceded the recruitment of ILC2s to atopic dermatitis-
like skin lesions in mice. Interestingly, basophil-derived IL-4
was required for the optimal recruitment of ILC2s to these
skin lesions, and ILC2s expressed the IL-4 receptor, suggest-
ing a novel type of ILC2 regulation [61]. However, it remains
to be established whether this applies to ILC2s at other loca-
tions and whether ILC2s are also able to affect basophils.
Furthermore, depletion of basophils in a papain-induced pul-
monary inflammation model had no effect on pulmonary eo-
sinophilia, which argues against a major role of basophils in
pulmonary inflammation and ILC2 regulation [62].
Interaction of ILC2s with the adaptive immune system
ILC2 research has focused on the ability of ILC2s to secrete
type 2 cytokines and thereby enhance the activity of innate
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immune cells (e.g., eosinophils) in allergic asthma.
Interestingly, recent studies suggest that ILC2s may not only
affect innate cells but also contribute to the activity of adaptive
immune cells (e.g., Th2 cells) in allergic asthma. For example,
Gold et al. investigated the contribution of ILC2s to the adap-
tive immune response to HDM. ILC2-deficient Rorasg/sg
BMT mice (irradiated WT host mice transplanted with
Rorasg/sg BM) showed impaired leukocyte infiltration in the
lungs, as well as reduced serum levels of HDM-specific IgE,
compared to WT BMT mice after HDM exposure [63]. Th2
cells amplify allergic inflammation, and therefore ILC2-
mediated activation of Th2 cells may have large implications
for the overall contribution of ILC2s to allergic asthma.
ILC2s affect initiation of the adaptive immune response
via DCs
ILC2smight affect the adaptive immune response by influenc-
ing Th2 cell differentiation (possibly via DCs), and/or by
influencing the activity of primed Th2 cells or IgE-
producing B cells. This question was assessed by Halim et
al., who compared papain-induced Th2 cell generation in the
mediastinal LN (mLN) of WT BMT mice versus Rorasg/sg
BMT mice [64]. Via intracellular cytokine staining, they
showed that Th2 cell differentiation occurred 6 days after
papain treatment in the mLN of WT mice, and that this re-
sponse was impaired in Rorasg/sg BMTmice compared toWT
BMT mice. Similar results were found in HDM- or fungal
protease-allergen-treated mice. Notably, the adoptive transfer
ofWT ILC2s into papain-treatedRorasg/sg BMTmice restored
the number of Th2 cells [64]. Together, these results suggested
that ILC2s are involved in driving Th2 cell differentiation in
response to allergen encounter.
Although it has been shown that ILC2s accumulate in the
mLN during airway inflammation, it remains the question
whether they play a direct role in skewing naive Tcells toward
Th2 differentiation. As IL-4 plays a critical role in Th2 cell
differentiation [65], it was therefore investigated whether
ILC2s might promote Th2 cell differentiation via IL-4.
Some studies report that pulmonary ILC2s have the ability
to produce small amounts of IL-4 after in vivo activation with
IL-25 or IL-33 [10], OVA[10], papain [14], and HDM [10,
66], as measured by ELISA or intracellular FACS staining. IL-
4 production by ILC2s may depend on specific activating
stimuli, as LTD4, as shown in vitro. In contrast, IL-33 was
not able to induce IL-4 production by ILC2s in vitro [16]. It
remains to be determined whether ILC2s also produce IL-4 in
the close proximity of naïve CD4+ T cells in vivo.
However, differentiation toward Th2 cells can occur in an
IL-4-independent pathway, as shown by the induction of Th2
cells in IL-4-deficient mice after N. brasiliensis infection [67].
In concordance, Halim et al. found that papain-challenged
Il4−/− mice displayed a normal Th2 response. Interestingly,
they found that papain-treated Il13−/− mice had strongly de-
creased Th2 cell numbers in the mLN compared to WT mice.
Intracellular cytokine staining showed that ILC2s were the
predominant source of IL-13 after papain treatment, suggest-
ing that ILC2-derived IL-13 promoted Th2 cell differentia-
tion. This was confirmed in a transgenic TCRmodel, in which
CFSE-labeled OVA-specific OT-II T cells were injected into
WT BMT mice or Rorasg/sg BMT mice. OVA plus papain
treatment induced normal T cell proliferation but failed to
induce Th2 cell differentiation in Rorasg/sg BMT mice. This
effect could be rescued by adoptive transfer of WT ILC2, but
not by Il13−/− ILC2, indicating that ILC2-derived IL-13 is
required for papain-induced Th2 differentiation. Notably, the
IL-13 receptor was present on DCs but not on CD4+ T cells,
suggesting that this effect was mediated via DCs. Indeed, DCs
with CD40+ expression (a surface marker that is implied to
induce Th2 differentiation) were present at normal numbers in
the lungs but strongly decreased in the mLN of Rorasg/sg BMT
mice, which could be rescued by IL-13 injections. Subsequent
in vitro migration assays showed that IL-13 increased the ca-
pacity of DCs to migrate toward a CCL21 gradient, which is
highly expressed in the lymph node [64].
Together, these results indicate that ILC2s might facilitate
Th2 differentiation via inducing efficient migration of activat-
ed DCs from the lung to the mLN [64]. The question remains
whether ILC2s might skew DCs toward a pro-Th2 DC phe-
notype, e.g., expression of OX40L, ICOS-L, Notch ligand
Jagged1, and secreting cytokine IL-6 but not IL-12.
Interactions between ILC2s and CD4+ T cells
In addition to an indirect, DC-mediated interaction, recent
studies suggest that pulmonary ILC2s and CD4+ Tcells might
interact directly with each other [68, 69]. In vitro studies sug-
gested that CD4+ Tcells can activate ILC2s via IL-2 signaling,
which corresponds with earlier findings of IL-2-mediated ac-
tivation of ILC2s [32, 42]. Wilhelm et al. demonstrated that
IL-2 treatment enhanced the autocrine IL-9 production by
ILC2s, resulting in increased IL-5 and IL-13 [14]. In contrast,
Mirchandani did not find an increased IL-9 production after
IL-2 treatment [68], suggesting that IL-2 can have distinct
stimulating effects on ILC2s in different settings.
On the other hand, the presence of ILC2s also enhanced
anti-CD3/anti-CD28-induced CD4+ T cell proliferation [69]
and type 2 cytokine production [68, 69], whereas IFN-γ pro-
duction remained constant [69] or even decreased [68]. ILC2s
and CD4+ T cells likely interacted in a cell contact-dependent
manner, because separation of CD4+ T cells and ILC2s in a
transwell system strongly decreased ILC2-dependent CD4+ T
cells activation [68]. Drake et al. showed that increased type 2
cytokine production by cocultured ILC2s and CD4+ T cells
was partly dependent on OX40L expression by ILC2s, likely
through interaction with OX40 on CD4+ T cells [69]. OX40L
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expression by DCs has been shown before to drive Th2 cell
differentiation [70]. In addition, Drake et al. found that ILC2-
derived IL-4 might play a role in CD4+ T cell activation, since
coculturing of Il4−/− ILC2s with WT CD4+ T cells strongly
diminished total IL-5 and IL-13 production as compared to
coculturing WT ILC2s and CD4+ T cells [69]. However, it
should be noted that the authors measured total cytokine pro-
duction by cocultured ILC2s and CD4+ T cells and did not
formally prove which cell type was the source of these cyto-
kines [69]. In contrast, Mirchandani et al. found that ILC2-
mediated activation of CD4+ T cells was independent of
OX40- and IL-4 signaling [68]. Instead, their results suggested
that ILC2s might interact with CD4+ T cells by presenting
antigens on MHCII, as OVA-peptide-pulsed ILC2s could in-
duce proliferation of OVA-specific transgenic DO11.10 T
cells, which was blocked by adding a neutralizing MHCII
antibody [68].
The potential capacity of ILC2s to present antigens was
demonstrated by Oliphant et al. [13]. ILC2s that were isolated
from murine mesenteric lymph nodes expressed MHCII,
CD80, and CD86. Furthermore, they were able to endocytose
and process antigen in vitro, albeit at a much lower efficiency
than DCs and B cells, but could not induce proliferation of
OVA-specific OT-II transgenic (OTII Tg) T cells after cocul-
ture unless OVA peptide was added [13]. The proliferation
was abolished after using a neutralizing MHCII antibody or
by using MhcII−/− ILC2s but also after combined treatment
with neutralizing CD80 and CD86 antibodies [13]. ILC2s
may provide T cells with costimulation on CD28 [13]. The
capacity to present allergens in vivo awaits confirmation and
in comparison to other APCs, like DCs. Additionally, the ca-
pacity to present antigens may be specific for certain ILC2
subsets. For example, mLN ILC2s had substantially higher
MHCII expression than bronchoalveolar and lung ILC2s
[13]. Coculturing of peptide-pulsed ILC2s also strongly en-
hanced ILC2 proliferation and type 2 cytokine production, as
compared to controls lacking peptide. Interestingly, this effect
was blocked by treatment with neutralizing antibodies against
MHCII, CD80, CD86, or IL-2 [13]. These results implied that
ILC2-expressed MHCII, CD80, and CD86 were not only re-
quired for ILC2-mediated activation of CD4+ T cells but also
for activation of ILC2s themselves, possibly by stimulating
CD4+ T cells to provide them with IL-2.
To investigate reciprocal activation between ILC2s and
CD4+ T cells in vivo, cotransfer experiments were performed
in murine models of allergic asthma [68, 69]. Il7ra−/− mice
(which are deficient in ILCs and T cells) were reconstituted
with ILC2 and/or CD4+ T cells from naive mice, and subse-
quently treated with a combination of OVA and a cysteine
protease (bromelain)[69]. OVA plus bromelain inhalation in-
duced a small increase in pulmonary eosinophilia and IL-13
levels in the BAL of mice that had been reconstituted with
ILC2s or CD4+ T cells, whereas a large increase was found in
mice that had been reconstituted with ILC2s and CD4+ Tcells.
Remarkably, the latter increase was larger than the additive
effect of ILC2- and CD4+ T cell-transfer alone, which sug-
gested a synergistic effect [69]. Similar enhancing effects of
ILC2s on CD4+ T cell proliferation and type 2 cytokine pro-
duction were found by Mirchandani et al., who cotransferred
ILC2s and DO11.10 CD4+ T cells in OVA plus IL-33-treated
ST2-deficient mice [68]. However, for both studies, it cannot
be excluded that interactions between ILC2s and CD4+ Tcells
in vivo were mediated via another cell type, for example DCs.
A potential direct interaction between CD4+ T cells and ILC2
in vivo was assessed by Oliphant et al., who tested the require-
ment for MHCII expression by ILC2 for expulsion of intesti-
nal N. brasiliensis in Il13−/− mice [13]. Il13−/− mice showed
delayed helminth expulsion, which could be rescued by adop-
tive transfer of WT ILC2s, but notMhcII−/− ILC2s. However,
no difference in CD4+ T cell numbers could be observed in
mice that had received WT ILC2 versus MhcII−/− ILC2 [13].
This implied that ILC2-expressed MHCII was required for
efficient helminth expulsion, yet not for proliferation of
CD4+ T cells in vivo. Possibly ILC2s were dependent on
MHCII expression to receive activating signals from CD4+
T cells (e.g., IL-2).
Although ILC2s contribute to the initiation of Th2 cell
differentiation, they do not seem to be required for the activa-
tion of memory Th2 cells. ILC2 deficient mice were capable
of eliciting a full-blown airway inflammation, when initial
Th2 cell differentiation was induced by an i.p. injection with
OVAwith the adjuvant alum [63].
Recently, it was described that regulatory Tcells might also
regulate activation of ILC2s besides their recognized suppres-
sive effect on effector Th2 cells. In a self-limited OVA-in-
duced allergic airway inflammation, it was demonstrated that
the de novo generation of regulatory T cells coincided with a
decrease in IL-13 production by ILC2s in a TGF-β-dependent
manner [71]. Interestingly, the persistence of airway inflam-
mation, airway hyperreactivity and remodeling was demon-
strated to be dependent on ILC2s rather than on antigen spe-
cific T cells in a chronic asthma model [72].
Interactions between ILC2s and B cells
One of the initial reports that characterized ILC2s described
interactions between ILC2s and B cells. Coculturing of ILC2s
from the FALC with splenic B cells enhanced IgA production.
Furthermore, ILC2s enhanced proliferation of peritoneal B1
cells but not B2 cells, which was dependent on ILC2-derived
IL-5. In addition, B1 cells that were adoptively transferred into
Rag2−/− mice proliferated more than when they were trans-
ferred into Rag2−/−Il2rg−/− mice, and cotransfer of B1 cells
with ILC2 but not CD4+ T cells into Rag2−/−Il2rg−/− mice
induced B1 cell proliferation [32]. Therefore, the authors sug-
gested that ILC2s were able to activate B1 cells in vivo.
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However, these results have not been replicated and might not
be relevant for the role of ILC2s in allergic asthma.
Recently, a novel Thy-1+ Sca-1+ ILC2-like cell type was
described in the murine spleen that did not express c-Kit, IL-
7R, or ST2, but instead expressed IL-18R. These ILC2-like
cells proliferated and produced IL-5 and IL-13 after in vitro
stimulation with IL-2 plus IL-18, or after coculture with B
cells. Interestingly, coculturing these ILC2-like cells with
anti-CD40 plus IL-4-treated B cells strongly enhanced IgE
production. This effect was abolished when the cell popula-
tions were separated in a transwell system, suggesting a
contact-dependent interaction [73].
An interaction between ILC2s and B cells might be medi-
ated via the costimulatory molecule ICOS, that is highly
expressed by ILC2s and may interact with ICOS-ligand-
expressing B cells [31]. Interestingly, ILC2s also express
ICOS-L and provide self-stimulation, important for survival
and cytokine production. The ICOS-ICOS-L interaction was
demonstrated to be required for murine and human ILC2 me-
diated induction of airway inflammation and hyperreactivity
[74]. However, these interactions as well as their potential
consequences for B cell function and type 2 responses warrant
further studies.
ILC2s in human allergic asthma
The earliest association between ILC2s and human asthma
was probably described in 2009 by Allakhverdi et al., al-
though ILC2s were not yet characterized at that time [75].
The authors found CD34+ non-B/T cells in the blood that
expressed receptors for TSLP and IL-33, and that responded
to these cytokines with rapid release of IL-5 and IL-13, in
vitro. These cells were present in the sputum of allergic asth-
ma patients, but not in the sputum of healthy individuals.
More importantly, their numbers increased in response to spe-
cific allergen inhalation [75], suggesting a role of these ILC2-
like cells in allergic asthma. However, it is unclear if these
cells are the same as the Lin− CD127+ CD161+ CRTH2+
ILC2s that were later characterized in humans [38].
Human ILC2s are present in both the naive and inflamed
lung, and they have the ability to produce large amounts of
type 2 cytokines after activation with IL-25, IL-33, or TSLP
[11, 30]. Interestingly, it was shown that asthma patients have
increased expression of IL-25, IL-33, and TSLP in the lungs
[76–78]. Furthermore, genetic variants of TSLP, IL-17RB, IL-
33, and ST2 have been associated with increased susceptibil-
ity to asthma [79–82]. Recently, several groups have investi-
gated the role of ILC2s in the airways of asthmatics.
Christianson et al. demonstrated an increased frequency of
IL-13 producing ILC2s in BALF in comparison to disease
control subjects. Interestingly, also the concentration of IL-
33 was increased in BALF of asthmatics and correlated with
disease severity [72]. In corticosteroid resistant severe asthma
patients higher levels of ILC2s in induced sputum were ob-
served compared with healthy controls but also with mild
asthmatics. More importantly, ILC2s were the predominant
source of IL-5 and IL-13, despite CD4+ T cells were more
abundant [83]. Also in children with severe-therapy resis-
tant-asthma, an increased number of ILC2s was found in in-
duced sputum compared with children with lower respiratory
tract infections without asthma [84]. It was shown before by
Bartemes et al. that PBMCs from allergic asthma patients
produced significantly larger amounts of IL-5 and IL-13 after
treatment with IL-25 or IL-33 than PBMCs from allergic rhi-
nitis patients or healthy controls. In addition, the total number
of blood ILC2s and the proportion of ILC2s in PBMCs were
significantly increased in allergic asthma patients compared to
allergic rhinitis patients or healthy controls, suggesting that
the enhanced type 2 response by PBMCs from allergic asthma
patients might be caused by the increased presence of ILC2s
[85]. In contrast, another study showed that ILC2s were pres-
ent in similar numbers in the blood from healthy controls, mild
allergic asthma patients, and severe allergic asthma patients
[30]. However, an increased activation status of ILC2s during
disease might still result in increased type 2 cytokine produc-
tion or increased reactivity toward activating stimuli.
ILC2s have also been associated with chronic rhino-
sinusitis (CRS). CRS is characterized by inflammation of the
mucosal surfaces of the nose and para-nasal sinuses, and it
often coexists with allergic asthma [86]. The presence of
ILC2s was enriched in the nasal polyps of CRS patients com-
pared to noninflamed nose tissue of CRS patients without
nasal polyps or healthy controls [38, 87, 88]. Notably, CRS
without nasal polyps and CRS with nasal polyps are typically
associated with type 1 or type 2 inflammation, respectively
[89]. Furthermore, it was shown that epithelial cells from CRS
patients with nasal polyps had increased expression of TSLP
and IL-33 [88, 90].
Recent studies showed that ILC2s are enriched in
skin lesions of atopic dermatitis patients [36, 40].
Atopic dermatitis is a chronic inflammatory skin disease
that is characterized by eosinophilic infiltration and high
serum IgE levels [91]. Similar to allergic asthma and
CRS, atopic dermatitis has been associated with in-
creased expression of TSLP, IL-25, and IL-33 in the
skin [92, 93]. ILC2s from skin lesions of atopic derma-
titis patients showed increased expression of IL-17RB,
ST2, and TSLPR compared to skin ILC2s from healthy
controls, suggesting a role in the maintenance of the
inflammation [40, 85]. Together, these studies indicate
that ILC2s could be involved in several Th2-mediated
disorders. In particular, ILC2s might be important key
players in the pathogenesis of severe asthma for which
there are limited treatment options. ILC2s might repre-
sent a potential therapeutic target.
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Conclusion and clinical implications
Allergic asthma is a complex disease that is mediated by var-
ious interactions between immune cells and structural cells
(Fig. 1). Th2 cells are central effector cells in this process
through their secretion of type 2 cytokines that drive IgE pro-
duction and control the activity of various innate immune
cells. The recently identified ILC2s are hypothesized to coor-
dinate epithelial responses to allergen encounter and represent
another major source of type 2 cytokines. Many studies sup-
port that ILC2s are involved in asthma pathogenesis by
interacting with structural cells and the innate immune system.
Importantly, recent studies indicate that ILC2s also amplify
the adaptive type 2 response.
However, in order to fully assess their potential as a thera-
peutic target, some main questions remain to be answered.
Firstly, the role of ILC2s in the immunopathology in human
asthma needs to be further elucidated, as so far only associa-
tions have been found between increased presence of ILC2 or
ILC2-activating stimuli and allergic disease. Secondly, the
finding that ILC2s can induce eosinophil recruitment, mucus
hyperproduction, and airway hyperresponsiveness in the ab-
sence of Tand B cells in mice warrants further investigation of
the relative contribution of ILC2s in comparison with the Th2-
IgE-mast cell pathway to the development of shortness of
breath, the most relevant clinical symptom in human asthma.
In addition, the relative contribution of IL-5 and IL-13 pro-
duction by ILC2s in human asthma in comparison to Th2
cells, other innate cells and structural cells, like epithelial cells
[94], needs to be further elucidated. If it is proven that ILC2s
contribute to the long-term exacerbations and chronic disease
in allergic asthma, it remains an interesting challenge to deter-
mine how ILC2s should be targeted. Intervening with the
activation of ILC2s might be difficult due to several other
activation pathways that could bypass the blocked activation
route. Indeed, only the combined blockage of IL-25, IL-33
and TSLP signaling could abolish ILC2 activation in response
to chitin inhalation in mice [19]. Likewise, intervening with
the type 2 effector cytokines that are provided by ILC2s might
require inhibition of a combination of cytokines.
Importantly, direct intervention with ILC2 function re-
quires further elucidation of their potential beneficial role in
the respiratory system. ILC2s have been shown to promote
tissue repair and lung homeostasis during influenza infection
by secretion of amphiregulin. Interestingly, amphiregulin is an
epidermal growth factor receptor (EGFR) ligand that has been
linked to the regulation of tissue repair and remodeling in the
context of acute asthma attacks and epithelial injury [95].
Inhibition of ILC2s during influenza or respiratory virus-
induced asthma exacerbations may have both beneficial and
detrimental effects [11, 22].
In conclusion, a remarkable amount of knowledge on ILC2
function has been gained since their discovery only six years
ago. Murine studies suggest that these cells play an important
role in the immunopathology of allergic asthma by interacting
with both structural as innate immune and adaptive type 2
cells during allergen sensitization and acute inflammation.
Now, the future challenges lie in further elucidation of both
the pathogenic and protective functions of ILC2s in acute and
chronic human allergic asthma, in order to better comprehend
the complex pathogenesis of this disease and facilitate the
design of novel therapeutics.
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